Irbesartan Drug Recall Lawsuits

High Blood Pressure Drug Recalled – Linked to Cancer

Irbesartan, an angiotensin II receptor blocker (ARB), the same class of drug as Valsartan, has been nationally recalled by the FDA due to potential cancer risk. Used as a standalone drug or in conjunction with other medications, Irbesartan is prescribed to treat hypertension (high blood pressure). The drug can also be prescribed to treat high blood pressure with diabetic nephropathy. A complication of type 2 diabetes, diabetic nephropathy can impair kidney function. Like other ARBs the drug works by blocking the action of natural substances that constrict blood vessels, allowing the heart to work more efficiently and blood to flow more smoothly.

Known Carcinogen N-Nitrosodimethylamine (NDEA) Found in Irbesartan

Often associated with industrial processes*, NDEA is a synthetic light-sensitive, volatile, clear yellow oil that is soluble in water, lipids and other organic solvents. It may be used as an additive in lubricants, as a gasoline and/or a stabilizer for industry materials. It is also used in experimental research to induce liver tumorigenesis. NDEA has been classified as a probable human carcinogen by the International Agency for Research on Cancer (IARC). 

N-nitrosodiethylamine (NDEA) has been found in Irbesartan and may cause tumors to individuals who have taken (or are taking) Irbesartan. All forms of the drug (including 75 mg, 150 mg, and 300 mg tablets) have been associated with potential cancer risks due to the NDEA impurity. This group of “sartan” drugs have all universally been recalled making it one of the largest recalls in FDA history.  

*Long-term exposure to NDEA may increase the risk of digestive system cancers as it is known to target the liver, esophagus, and stomach in animals.

Nationwide Recall of Hypertension Drug Irbesartan

Sciegen Pharmaceuticals, Inc. has issued a voluntary nationwide recall of Irbesartan tablets, USP 75 mg, 150 mg, and 300 mg due to the potential cancer risk related to the NDEA impurity. The October 2018 recall affects multiple batches of the drug, supplied by Aurobindo Pharam Limited, headquartered in India. The recalled ScieGen Pharmaceuticals Inc. Irbesartan was labeled as Westminster Pharmaceuticals and Golden State Medical Supply, Inc., a list of the recalled lot numbers is included in the recall.

Irbesartan Related Injuries

Was My Irbesartan Medication Contaminated?

If you have taken Irbesartan in the past or are currently taking Irbesartan you can search the FDA’s official ARB recall list. Search by either the drug name, manufacturer, National Drug Code (NDC), lot number, or expiration date. Almost all this information can be found on the label of your medication. Harding Mazzotti, LLP attorneys are your tenacious Irbesartan recall lawyers with the experience you need to deliver the justice you deserve.

Exposure to N-Nitrosodimethylamine (NDEA) may cause cancer. Injuries from NDEA exposure include but are not limited to:

  • Stomach Cancer
  • Intestinal Cancer
  • Colorectal Cancer (Colon Cancer)
  • Esophageal Cancer
  • Liver Cancer
  • Prostate Cancer
  • Leukemia (Blood Cancer)
  • Multiple Myeloma Cancer
  • Non-Hodgkin’s Lymphoma
  • Pancreatic Cancer

*The FDA has advised patients to continue to take the recalled medication until an appropriate alternative product is provided.

Get Irbesartan Drug Recall Help Today

Not everyone who has taken Irbesartan will be able to file for a personal injury lawsuit depending on their individual circumstances. It is important that you consult with a personal injury lawyer to see if you have a case. While a recall letter may advise you to return the product to the manufacturer, do not dispose of your medication. Hold on to it as the medication may become useful in your case. 

If you have been taking the HBP medication Irbesartan contaminated with NDEA and are suffering from liver, kidney, or other digestive cancers, you may be entitled to compensation. Click, Chat or call our reputable defective drug attorneys at 1800LAW1010 24/7 for a free case evaluation. We serve clients in various locations throughout New York as well as Vermont and Massachusetts.